Delivery Order SPE2DB22D1106-SPE2DB25FEKE8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,248.90 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product...
- The Defense Logistics Agency awarded a delivery order valued at $3,155.66 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, representing a critical pharmaceutical...
- The Defense Logistics Agency awarded a $2,145.94 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of NovoLog 100 Unit/ML vials (10 ML units). This is a firm fixed-price, non-set-aside contract with a completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes management and represents a critical pharmaceutical commodity within the...
- The Defense Logistics Agency awarded a delivery order valued at $2,020.06 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 14, 2025, with completion expected by July 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. NovoLog is a rapid-acting insulin analog used in diabetes management, representing the type of critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a contract value of $1,248.90. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The order is set to be completed by September 11, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting...
- The Defense Logistics Agency awarded a $2,737.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL). The contract, which is a child order under a larger indefinite delivery contract, carries an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a non-competitive, competitively awarded transaction...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,761.74 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL vials (10mL units). This non-set-aside, firm fixed-price contract represents a single delivery order with an ultimate completion date of September 3, 2025. The award was issued on September 2, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product...
- The Defense Logistics Agency awarded a $2,443.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 14, 2025, with an ultimate completion date of July 15, 2025. This is a non-set-aside contract representing a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 billion through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $3,362.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL), with an ultimate completion date of September 19, 2025. This contract was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency awarded a delivery order valued at $2,372.92 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL vials (10 mL) on June 18, 2025, with an ultimate completion date of June 20, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEKE8Delivery Order
The Defense Logistics Agency awarded a $1,296.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child delivery order under a larger contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, reflecting the ongoing pharmaceutical supply requirements of the military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and prime vendor for federal medical procurement, AmerisourceBergen supplies critical medications and medical commodities to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. The company's extensive portfolio under this IDC encompasses specialty medications, vaccines, and medical supplies across multiple therapeutic domains, demonstrating its role as a comprehensive pharmaceutical support provider for federal defense and healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 4/23/25 |